BR112014011518A2 - liberação imediata da formulação 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluorometil)fenil] benzamida - Google Patents

liberação imediata da formulação 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluorometil)fenil] benzamida

Info

Publication number
BR112014011518A2
BR112014011518A2 BR112014011518A BR112014011518A BR112014011518A2 BR 112014011518 A2 BR112014011518 A2 BR 112014011518A2 BR 112014011518 A BR112014011518 A BR 112014011518A BR 112014011518 A BR112014011518 A BR 112014011518A BR 112014011518 A2 BR112014011518 A2 BR 112014011518A2
Authority
BR
Brazil
Prior art keywords
methyl
benzamide
imidazol
pyridinyl
pyrimidinyl
Prior art date
Application number
BR112014011518A
Other languages
English (en)
Inventor
Makarov Alexey
Reese Comfort Ann
Sadashiv Bordawekar Mangesh
Li Ping
Li Shoufeng
Bhardwaj Upkar
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR112014011518A2 publication Critical patent/BR112014011518A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

resumo patente de invenção: "liberação imediata da formulação 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluorometil)fenil] benzamida". a presente invenção refere-se à forma de dosagem sólida de nilotinib divulgada, que compreende: (i) um núcleo compreendendo 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluorometil)fenil] benzamida ou a sal farmaceuticamente aceitável da mesma e excipientes; e (ii) pelo menos um polímero, o dito polímero revestindo o dito núcleo, em que a desintegração da dita forma de dosagem sólida é atrasada.
BR112014011518A 2011-11-14 2012-11-12 liberação imediata da formulação 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluorometil)fenil] benzamida BR112014011518A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161559281P 2011-11-14 2011-11-14
PCT/US2012/064610 WO2013074432A1 (en) 2011-11-14 2012-11-12 Immediate release 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-[5-(4-methyl- 1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide formulation

Publications (1)

Publication Number Publication Date
BR112014011518A2 true BR112014011518A2 (pt) 2017-05-16

Family

ID=47324402

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014011518A BR112014011518A2 (pt) 2011-11-14 2012-11-12 liberação imediata da formulação 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluorometil)fenil] benzamida

Country Status (22)

Country Link
EP (1) EP2779995A1 (pt)
JP (1) JP6275645B2 (pt)
KR (1) KR20140093230A (pt)
CN (1) CN103930094A (pt)
AR (1) AR088844A1 (pt)
BR (1) BR112014011518A2 (pt)
CA (1) CA2855503A1 (pt)
CL (1) CL2014001247A1 (pt)
CO (1) CO6960546A2 (pt)
EA (1) EA201490960A1 (pt)
GT (1) GT201400094A (pt)
HK (1) HK1197025A1 (pt)
IL (1) IL232480A0 (pt)
IN (1) IN2014DN03416A (pt)
MA (1) MA35636B1 (pt)
MX (1) MX2014005874A (pt)
PE (1) PE20141337A1 (pt)
SG (2) SG11201401476TA (pt)
TN (1) TN2014000177A1 (pt)
TW (1) TWI574690B (pt)
WO (1) WO2013074432A1 (pt)
ZA (1) ZA201402756B (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2792360A1 (en) 2013-04-18 2014-10-22 IP Gesellschaft für Management mbH (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV
CZ2017821A3 (cs) 2017-12-20 2019-07-03 Zentiva, K.S. Léková forma obsahující krystalický nilotinib
JP7378279B2 (ja) * 2019-11-18 2023-11-13 日本化薬株式会社 ニロチニブを有効成分とする医薬錠剤及びその製造方法
JP7489849B2 (ja) 2020-07-20 2024-05-24 日本化薬株式会社 ニロチニブ錠剤

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0215676D0 (en) * 2002-07-05 2002-08-14 Novartis Ag Organic compounds
GT200600315A (es) 2005-07-20 2007-03-19 Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida
GT200600316A (es) 2005-07-20 2007-04-02 Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.
EP1923053A1 (en) * 2006-09-27 2008-05-21 Novartis AG Pharmaceutical compositions comprising nilotinib or its salt
US20100136097A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
WO2012164578A1 (en) * 2011-06-02 2012-12-06 Hetero Research Foundation Compositions and methods for preparing immediate release formulations of nilotinib

Also Published As

Publication number Publication date
MA35636B1 (fr) 2014-11-01
EP2779995A1 (en) 2014-09-24
TN2014000177A1 (en) 2015-09-30
CN103930094A (zh) 2014-07-16
IN2014DN03416A (pt) 2015-06-26
AR088844A1 (es) 2014-07-10
WO2013074432A1 (en) 2013-05-23
CA2855503A1 (en) 2013-05-23
MX2014005874A (es) 2014-06-23
JP2014533283A (ja) 2014-12-11
NZ623844A (en) 2016-09-30
AU2012339829A1 (en) 2014-05-29
CL2014001247A1 (es) 2014-10-17
CO6960546A2 (es) 2014-05-30
TW201325594A (zh) 2013-07-01
SG11201401476TA (en) 2014-10-30
GT201400094A (es) 2017-09-28
IL232480A0 (en) 2014-06-30
ZA201402756B (en) 2015-04-29
EA201490960A1 (ru) 2014-08-29
PE20141337A1 (es) 2014-10-16
HK1197025A1 (en) 2015-01-02
JP6275645B2 (ja) 2018-02-07
AU2012339829B2 (en) 2016-05-12
SG10201707768RA (en) 2017-10-30
TWI574690B (zh) 2017-03-21
KR20140093230A (ko) 2014-07-25

Similar Documents

Publication Publication Date Title
BR112013032122A2 (pt) liberação modificada de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluorometil)fenil] benzamida solubilizada usando ácidos orgânicos
HRP20151399T1 (hr) Kinazni inhibitor koji regulira signalni put apoptoze
IL229199A (en) N– (2– {2– dimethylaminoethyl-methylamino} –4 – methoxy-5 - {[4– (1-methylindol-3-yl) pyrimidine-2-yl] amino} phenyl) prop-2-anamide and salts acceptable in pharmacy Her, pharmaceuticals that include her and its use in the manufacture of cancer drugs
UA115320C2 (uk) Інгібітори кінази
NZ602125A (en) Uses of dgat1 inhibitors
UA112055C2 (uk) Солі 4-[2-[[5-метил-1-(2-нафталініл)-1h-піразол-3-іл]оксі]етил]морфоліну
NZ600310A (en) 4-[2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine salts
NZ629636A (en) Liver x receptor (lxr) modulators for the treatment of dermal diseases, disorders and conditions
MY167216A (en) Kinase inhibitors
MA37455B1 (fr) Utilisation d'un dérivé de pyrazole dans le traitement d'exacerbations aigues d'une maladie pulmonaire obstructive chronique
BR112014011518A2 (pt) liberação imediata da formulação 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluorometil)fenil] benzamida
JP2009532438A5 (pt)
NZ590839A (en) Treatment of pulmonary arterial hypertension
NZ590177A (en) Use of pyrimidylaminobenzamide derivatives for the treatment of fibrosis
CR20210043A (es) Forma de dosificación farmacèutica administrable por vía oral con liberación modificada
JP2009511450A5 (pt)
HRP20171295T1 (hr) Derivat 6-okso-1,6-dihidro-piridazina za upotrebu za liječenje hepatocelularnog karcinoma (hcc)
NZ597864A (en) Methods and compositions for treating leukemia
TH152470A (th) สูตรตำรับ 4-เมธิล-3-[[4-(3-ไพริดินิล-2-ไพริมิดินิลอะมิโน1-n-[5-(4-เมธิล-1h-อิมิดาโซล-1-อิล)-3-(ไตรฟลูออโรเมธิล)ฟีนิล] เบนซาไมด์ชนิดปลดปล่อยทันที
TN2013000440A1 (en) Modified release of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-5-(4-methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide solubilized using organic acids
NZ624621A (en) Manufacturing process for pyrimidine derivatives
MA35842B1 (fr) Inhibiteurs de kinases
TH123958A (th) 5-(2-{[6-(2,2-ไดฟลูออโร-2-ฟีนิลเอทธอกซี)เฮกซิล]อะมิโน}-1-ไฮดรอกซีเอทธิล)-8-ไฮดรอกซีควิโนลิน-2(1h)-โอน สำหรับการบำบัดการทำงานของปอด

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2540 DE 10-09-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]